Rare pediatric Bednar tumor case highlights importance of histopathology and molecular testing in distinguishing uncommon dermatologic malignancies from benign pigmented lesions
Eli Lilly's JAK inhibitor demonstrated 80% scalp hair regrowth in 42.4% of adolescents with severe alopecia areata after just 36 weeks of treatment, outperforming placebo in the Phase 3 BRAVE-AA-PEDS trial.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Home light therapy shows promise for treating mild to moderate acne with fewer side effects than traditional medications, according to new research published in JAMA Dermatology.
FDA approves a prefilled syringe format for Purified Cortrophin Gel, reducing administration steps for patients with inflammatory and autoimmune conditions.